Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
ReNew
RNW
$2.48B
| $887K | ﹤0.01% |
161,200
+35,200
| +28% | +$206K |
|
|
SSKN
2602
DELISTED
Strata Skin Sciences
SSKN
| $886K | ﹤0.01% |
112,165
-1,740
| -2% | -$14.9K |
|
|
TRT
2603
Trio-Tech International
TRT
$116M
| $886K | ﹤0.01% |
393,826
-44,200
| -10% | -$108K |
|
2604
Liquidia Corp
LQDA
$6.66B
| $884K | ﹤0.01% |
138,800
-125,488
| -47% | -$674K |
|
2605
A.O. Smith
AOS
$8.45B
| $881K | ﹤0.01% |
15,400
-95,700
| -86% | -$5.35M |
|
2606
Planet Fitness
PLNT
$3.8B
| $875K | ﹤0.01% |
11,100
-13,800
| -55% | -$963K |
|
2607
Rimini Street
RMNI
$466M
| $875K | ﹤0.01% |
229,730
-24,300
| -10% | -$108K |
|
|
DSEY
2608
DELISTED
Diversey Holdings, Ltd. Ordinary Shares
DSEY
| $875K | ﹤0.01% |
205,400
+96,600
| +89% | +$473K |
|
2609
Enliven Therapeutics
ELVN
$4.31B
| $874K | ﹤0.01% |
53,450
-28,881
| -35% | -$462K |
|
2610
IHS Holding
IHS
$2.82B
| $871K | ﹤0.01% |
141,600
-26,200
| -16% | -$163K |
|
2611
UTStarcom
UTSI
$23.5M
| $870K | ﹤0.01% |
245,162
-25,101
| -9% | -$101K |
|
2612
First Trust Capital Strength ETF
FTCS
$8.02B
| $869K | ﹤0.01% |
+11,600
| New | +$856K |
|
2613
Treace Medical Concepts
TMCI
$312M
| $867K | ﹤0.01% |
37,700
-30,900
| -45% | -$711K |
|
2614
LGL Group
LGL
$93.6M
| $866K | ﹤0.01% |
213,834
-411,585
| -66% | -$1.91M |
|
2615
Praxis Precision Medicines
PRAX
$10.2B
| $866K | ﹤0.01% |
24,267
-5,674
| -19% | -$177K |
|
2616
IRIDEX
IRIX
$14.9M
| $865K | ﹤0.01% |
430,360
-22,700
| -5% | -$50.4K |
|
2617
Lightpath Technologies
LPTH
$953M
| $864K | ﹤0.01% |
708,000
-33,700
| -5% | -$38K |
|
2618
InnovAge Holding
INNV
$1.44B
| $863K | ﹤0.01% |
120,200
-2,400
| -2% | -$15.4K |
|
2619
Apyx Medical
APYX
$128M
| $862K | ﹤0.01% |
368,195
-59,900
| -14% | -$183K |
|
2620
ACM Research
ACMR
$5.6B
| $860K | ﹤0.01% |
+111,600
| New | +$946K |
|
|
SELF
2621
Global Self Storage
SELF
$61.1M
| $857K | ﹤0.01% |
175,700
+36,500
| +26% | +$187K |
|
|
USER
2622
DELISTED
UserTesting, Inc.
USER
| $856K | ﹤0.01% |
114,000
+84,693
| +289% | +$542K |
|
2623
Triumph Financial Inc
TFIN
$1.87B
| $855K | ﹤0.01% |
17,500
-7,400
| -30% | -$400K |
|
|
BNR
2624
Burning Rock Biotech
BNR
$93.1M
| $854K | ﹤0.01% |
37,950
-16,130
| -30% | -$368K |
|
|
HTBK
2625
DELISTED
Heritage Commerce
HTBK
| $854K | ﹤0.01% |
65,700
+10,100
| +18% | +$136K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.